BioCryst製藥 BCRX 深 滬
等待開盤 10-23 09:30:00 美东时间
7.08
+0.095
+1.36%
華盛通- 最 高7.155
- 今 開6.99
- 成交量 621.08万股
- 最 低 6.87
- 昨 收 6.985
- 總市值 14.80亿
- 52周最高 11.31
- 市盈率 靜 --
- 換手率 2.97%
- 52周最低 6.00
- 委 比 82.96%
- 總股本 2.09亿
- 歷史最高 19.99
- 量 比 0.71
- 振 幅 4.08%
- 歷史最低 1.08
- 每 手 1
- 風險率 1.06%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多美股大行评级 | 贝莱德、花旗、摩根大通、富国银行均获上调目标价！汇丰上调超微公司目标价升至310美元
今日重点评级关注：Roth Capital：维持Cingulate"买入"评级，目标价从10美元升至17美元；JMP证券：维持BioCryst Pharma"跑赢大市"评级，目标价从17美元升至27美元
10-16 10:43
TD Cowen Reinstates Buy on BioCryst Pharma, Announces $30 Price Target
TD Cowen analyst Stacy Ku reinstates BioCryst Pharma (NASDAQ:BCRX) with a Buy and announces $30 price target.
10-15 22:15
12 Health Care Stocks Moving In Tuesday's Intraday Session
Gainers Strata Skin Sciences (NASDAQ:SSKN) shares increased by 44.9% to $2.23 ...
10-15 01:06
BioCryst to buy Astria Therapeutics for $13 per share
BioCryst Pharmaceuticals (NASDAQ:BCRX) has agreed to acquire biopharmaceutical firm Astria Therapeutics (NASDAQ:ATXS) for a mix of cash and stock representing an implied value of $13.00 per Astria sha...
10-14 19:20
BioCryst to Acquire Astria Therapeutics, Strengthening Presence in HAE, Transforming Growth Profile
BioCryst Pharmaceuticals has agreed to acquire Astria Therapeutics for approximately $700 million in enterprise value, with the aim of adding Astria's Phase 3 HAE drug candidate, navenibart, to its portfolio. The deal is expected to solidify double-digit growth for BioCryst's HAE division over the next decade and maintain profitability. Navenibart is a long-acting, injectable therapy with a differentiated dosing schedule, addressing unmet needs i...
10-14 11:00
BioCryst Pharmaceuticals And Biocryst Ireland Entered Into A Trademark License Agreement
-SEC Filing
10-01 21:37
BioCryst Completes Sale of European ORLADEYO® (berotralstat) Business
BuyCryst Pharmaceuticals completed the sale of its European ORLADEYO business to Neopharmed Gentili for $250 million, with up to $14 million in future milestones. BioCryst will focus on U.S. sales while Neopharmed Gentili handles commercialization in Europe. The transaction boosts BioCryst's operating margin, simplifies operations, and enables debt repayment. ORLADEYO's commercial success is expected to continue globally.
10-01 11:00
BioCardia Announces CardiAMP Chronic Myocardial Ischemia Trial Top Line Data of Roll-in Cohort Show Improved Exercise Tolerance and Reduced Angina Episodes at Six-Month Primary Follow-up
BioCardia, Inc. announced positive results from its open-label CardiAMP Cell Therapy trial for patients with chronic myocardial ischemia and refractory angina. The minimally invasive therapy showed significant improvement, with patients experiencing an average 80-second increase in exercise tolerance and an 82% reduction in angina episodes at six months. These results outperform existing FDA-approved treatments like Ranolazine and EECP. CardiAMP ...
09-18 11:00
BioCardia CEO Peter Altman to Present at the H. C. Wainwright 27th Annual Global Investment Conference in New York City September 8-10, 2025
Peter Altman, PhD., President and CEO of BioCardia, Inc., will present a corporate update at the H. C. Wainwright 27th Annual Global Investment Conference in New York City on September 10, 2025. His presentation will include recent progress on the company’s clinical cell therapy programs for ischemic heart disease, regulatory activities for CardiAMP® cell therapy and the Helix™ delivery catheter, and updates on partnerships and funding for the Ca...
09-04 13:00
Ionis Pharma Wins FDA Nod For First RNA-Targeted Therapy For Rare Genetic Swelling Disorder
FDA approved Ionis' Dawnzera for hereditary angioedema, showing up to 87% attack reduction and strong results in switch patients.
08-22 02:24
